Edoxaban versus warfarin for venous thromboembolism

New England Journal of Medicine

Volumn 370, Issue 1, 2014, Pages 80-81

  Haft, Jacob I ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; ENOXAPARIN;

BLEEDING; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INCIDENCE; LETTER; PATIENT ASSESSMENT; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; FEMALE; MALE; BRAIN HEMORRHAGE; DISEASE ASSOCIATION; DRUG EFFECT; FATALITY; RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT;

ANTICOAGULANTS; ENOXAPARIN; FEMALE; HUMANS; MALE; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84892176349     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1313883     Document Type: Letter

References (1)

1. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15.